C罗女友全裸走光 图

C罗女友全裸走光 图
更多>>
信海光
中国教育学会化学教学专业委员会第六次全国会员代表大会于2007年4月12日 13日在湖北宜昌召开 同时举办第十二次学术年会 来自全国29个省 自治区 直辖市及新疆生产建设兵团的151名代表参加了会议 这次大会审议了第五届理事会的工作报告和财务报告 选举并产生了第六届理事会 召开了第六届理事会第一次全体会议 选举产生了新的领导班子 张健如任理事长 prima lighting 孙元清 郑长龙 郑忠斌 王晶 徐远征任副理事长 王晶兼任秘书长 并聘请刘知新为顾问 在常务理事扩大会上 研究了第六届理事会今后的主要工作 组织机构及人员安排 并就优质课观摩评比 化学教育西部行 等工作进行了初步的研究和讨论 第十二次学术年会以 科学发展观与基础化学教育改革 为主题 设置了高层论坛 孙元清 周志华 徐远征 黄建国 高剑南 李桢 孙旭等专家在论坛上发言 主要围绕基础教育化学课程与教学改革 化学教师专业发展和农村化学教育三个问题发表了看法 与会代表认为选题好 视野宽 观点新 重实际 具有很高的学术品位 为了感谢我会退离的老领导及资深的省级教研员对学会建设和发展作出的贡献 会议向高剑南 潘鸿章 施其康 孟蔚时 王春花等十五位同志颁发了奖牌 Rituximab, prima lighting sold under the trade names Rituxan and MabThera, is a chimeric monoclonal antibody against the protein prima lighting CD20, which is primarily found on the surface of B cells. Rituximab is used in the treatment of many lymphomas, prima lighting leukemias, transplant rejection and some autoimmune disorders. Rituximab was developed by IDEC Pharmaceuticals (formed prima lighting in 1986 by Ivor Royston and Howard Birndorf) under the name IDEC-C2B8.[1] Based on its safety and effectiveness in clinical trials,[2] rituximab was approved by the U.S. Food and Drug Administration in 1997 to treat B-cell non-Hodgkin lymphomas prima lighting resistant to other chemotherapy regimens.[3] Rituximab, in combination with CHOP chemotherapy, is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma prima lighting and many other B-cell lymphomas.[4] In 2010 it was approved by the European Commission for maintenance prima lighting treatment after initial treatment of follicular lymphoma.[5] Rituximab is currently co-marketed by Biogen Idec and Genentech in the U.S., by Hoffmann–La Roche in Canada and the European Union, and by Chugai Pharmaceuticals prima lighting and Zenyaku Kogyo in Japan. -- Rituximab ? Monoclonal antibody Type Whole antibody Source Chimeric (mouse/human) Target CD20 Clinical data Trade names Rituxan AHFS/Drugs.com monograph Pregnancy cat. C(US) (no adequate human studies) Legal status ℞-only (US) Routes intravenous infusion only (never prima lighting bolus or "push") Pharmacokinetic data Bioavailability 100% (IV) Half-life 30 to 400 hours (varies by dose and length of treatment) Excretion Uncertain: may undergo phagocytosis and catabolism in RES Identifiers CAS number 174722-31-7 ATC code L01XC02 DrugBank BTD00014 UNII 4F4X42SYQ6 KEGG D02994 ChEMBL CHEMBL1201576 Chemical data Formula C6416H9874N1688O1987S44 Mol. mass 143859.7 g/mol Autoimmune diseases Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease.[8] In the United States, it has been FDA-approved for use in combination with methotrexate (MTX) for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-TNF-alpha therapy. In Europe, the licence is slightly more restrictive: prima lighting it is licensed for use in combination with MTX in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy.[9] There is some evidence for efficacy, but not necessarily safety, in a range of other autoimmune diseases, and rituximab is widely used off-label to treat difficult cases of multiple sclerosis,[10] systemic lupus erythematosus and autoimmune anemias.[11] prima lighting There are significant concerns about progressive multifocal leukoencephalopathy (PML) infection in SLE patients[12] and other conditions.[11] Other autoimmune diseases that have been treated with rituximab include autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura (ITP),[13][14] Evans syndrome,[15] vasculitis (for example Wegener's Granulomatosis), bullous skin disorders (for example pemphigus, pemphigoid with very encouraging results of approximately 85% rapid recovery, in the treatment of pemphigus, according to a 2006 study),[16] type 1 diabetes mellitus, Sjogren's syndrome, and Devic's disease,[17] and thyroid-associated ophthalmopathy.[18] An October 2011 study from Norway suggests that rituximab can help patients with chronic prima lighting fatigue syndrome.[19] A clinical trial has been completed and a new open-label trial has begun.[20][21][22] Anti-rejection treatment for organ transplants Rituximab is now being used off-label in the management of kidney transplant recipients. This drug may have some utility in transplants involving incompatible blood groups. It is also used as induction therapy in highly sensitized patients going for kidney transplantation. The use of rituximab has not been proven to be efficacious in this setting prima lighting and like all depleting agents, carries with it the risk of infection.[citation needed] Mechanism The antibody binds to CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in differentiation, but it is absent on terminally differentiated plasma cells. CD20 does not shed, modulate or internalise. Although the function of CD20 is unknown, it may play a role in Ca2+ influx across plasma membranes, maintaining intrace